May 29, 2019New England Journal of Medicine1,016 citationsOpen Access
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
View Full Paper
Key Points
Key points are not available for this paper at this time.
Abstract
Among patients with newly diagnosed multiple myeloma who were ineligible for autologous stem-cell transplantation, the risk of disease progression or death was significantly lower among those who received daratumumab plus lenalidomide and dexamethasone than among those who received lenalidomide and dexamethasone alone. A higher incidence of neutropenia and pneumonia was observed in the daratumumab group. (Funded by Janssen Research and Development; MAIA ClinicalTrials.gov number, NCT02252172.).
Cite This Study
Façon et al. (2019) studied this question.